AAPL 173.18 2.2918% MSFT 397.84 0.7343% GOOG 168.46 1.7455% GOOGL 166.62 1.6844% AMZN 184.72 3.1955% NVDA 858.11 3.3357% META 441.84 0.6034% TSLA 180.1 0.0611% TSM 136.23 0.956% LLY 755.91 -2.683% V 267.61 0.1085% AVGO 1238.3 -0.3669% JPM 191.66 -0.1042% UNH 492.97 1.8302% NVO 124.02 -4.0167% WMT 59.71 1.4613% LVMUY 164.94 0.5609% XOM 116.24 0.181% LVMHF 825.49 0.3843% MA 441.1 -0.2194%
Last update at 2024-05-02T20:00:00Z
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | 2160.84M | 2183.06M | 2221.86M | -5293.83100M | 967.11M |
| Minority interest | 12.72M | 32.28M | -4.67600M | -9.15800M | 1.23M |
| Net income | 1745.29M | 1698.82M | 1539.93M | -3408.71600M | 855.37M |
| Selling general administrative | 5309.98M | 4848.96M | 3594.25M | 80.57M | 76.39M |
| Selling and marketing expenses | - | - | - | 23.73M | 2663.51M |
| Gross profit | 8959.49M | 8334.57M | 6774.43M | 5195.36M | 5138.31M |
| Reconciled depreciation | 963.90M | 693.89M | 514.79M | 391.06M | 462.41M |
| Ebit | 2734.64M | 2780.86M | 2894.01M | 2035.19M | 2025.35M |
| Ebitda | 3698.55M | 3474.76M | 3408.80M | 2426.25M | 2487.76M |
| Depreciation and amortization | 963.90M | 693.89M | 514.79M | 391.06M | 462.41M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 2340.73M | 2366.38M | 2354.20M | -5135.35400M | 1111.92M |
| Other operating expenses | 259487.81M | 235833.50M | 211145.04M | 187860.32M | 177576.72M |
| Interest expense | 228.93M | 210.67M | 182.54M | 137.88M | 157.77M |
| Tax provision | 428.26M | 516.52M | 677.25M | -1894.27300M | 112.97M |
| Interest income | 228.93M | 21.31M | 8.47M | 20.64M | 37.70M |
| Net interest income | -228.93100M | -210.67300M | -174.07400M | -137.88300M | -157.76900M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 428.26M | 516.52M | 677.25M | -1894.27300M | 112.97M |
| Total revenue | 262173.41M | 238587.01M | 213988.84M | 189893.93M | 179589.12M |
| Total operating expenses | 6273.89M | 5542.86M | 4099.42M | 3158.28M | 3125.91M |
| Cost of revenue | 253213.92M | 230252.44M | 207214.41M | 184698.56M | 174450.81M |
| Total other income expense net | -295.83800M | -359.78000M | -447.87200M | -7189.55300M | -887.52200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1732.58M | 1666.54M | 1544.61M | -3399.55800M | 854.13M |
| Net income applicable to common shares | 1745.29M | 1698.82M | 1539.93M | -3408.71600M | 855.37M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 62558.75M | 56560.62M | 57337.81M | 43947.86M | 39171.98M |
| Intangible assets | 14005.90M | 4332.74M | 5256.93M | 1886.11M | 2294.84M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1840.93M | 2192.50M | 2125.16M | 1533.95M | 1310.73M |
| Total liab | 61892.46M | 56489.34M | 56753.39M | 44787.50M | 36178.77M |
| Total stockholder equity | 666.29M | -289.78400M | 223.35M | -839.63600M | 2993.21M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2353.82M | 2214.59M | 192.07M | 1593.61M | 1057.21M |
| Common stock | 666.29M | 2.93M | 2.91M | 2.88M | 2.85M |
| Capital stock | - | 2.93M | 2.91M | 2.88M | 2.85M |
| Retained earnings | - | 2977.65M | 1670.51M | 518.34M | 4235.49M |
| Other liab | - | 7514.74M | 8064.89M | 7257.62M | 2243.08M |
| Good will | - | 8503.89M | 9030.53M | 6706.72M | 6705.51M |
| Other assets | 3618.85M | 1054.26M | 1017.60M | 697.97M | 269.07M |
| Cash | 2592.05M | 3388.19M | 2547.14M | 4597.75M | 3374.19M |
| Cash and equivalents | 2592.05M | 3388.19M | 2547.14M | 4597.75M | - |
| Total current liabilities | 48831.20M | 43477.96M | 41358.64M | 33853.08M | 29581.29M |
| Current deferred revenue | -641.34400M | - | 2856.41M | 53.15M | - |
| Net debt | 2195.41M | 2314.64M | 4136.78M | -478.22600M | 798.70M |
| Short term debt | 641.34M | 1070.47M | 300.21M | 501.26M | 139.01M |
| Short long term debt | 641.34M | 1070.47M | 300.21M | 501.26M | 139.01M |
| Short long term debt total | 4787.46M | 5702.83M | 6683.92M | 4119.52M | 4172.89M |
| Other stockholder equity | 666.29M | -1439.38700M | -1004.62400M | -1252.01900M | -1133.17300M |
| Property plant equipment | 2135.17M | 3079.98M | 3230.14M | 1928.33M | 1770.52M |
| Total current assets | 42798.83M | 39589.76M | 38802.61M | 33019.85M | 28132.05M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -13048.18200M | -14064.10400M | -9611.75000M | -6121.42600M |
| Short term investments | - | 0.00000M | 372.91M | - | - |
| Net receivables | 20911.08M | 18452.67M | 18389.05M | 14298.88M | 12386.88M |
| Long term debt | 4146.11M | 4632.36M | 6383.71M | 3618.26M | 4033.88M |
| Inventory | 17454.77M | 15556.39M | 15368.35M | 12589.28M | 11060.25M |
| Accounts payable | 45836.04M | 40192.89M | 38009.95M | 31705.06M | 28385.07M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -1830.97000M | -445.44200M | -108.83000M | -111.96500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3418.18M | 1761.66M | 1793.99M | 779.85M | 269.07M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 19759.92M | 16970.86M | 18535.20M | 10928.01M | 11039.93M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 4146.11M | 4632.36M | 6383.71M | 3618.26M | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -2602.46500M | -368.43700M | -6141.57700M | -379.87100M | -375.83200M |
| Change to liabilities | - | 3320.72M | 2049.17M | 3300.83M | 1561.05M |
| Total cashflows from investing activities | -2602.46500M | -368.43700M | -6141.57700M | -379.87100M | -375.83200M |
| Net borrowings | - | -923.10300M | 2216.55M | -32.00600M | -133.07300M |
| Total cash from financing activities | -2222.27800M | -1752.78000M | 1952.85M | -603.61700M | -1086.51300M |
| Change to operating activities | - | -854.72000M | 276.14M | 6751.01M | 234.22M |
| Net income | 1732.58M | 1666.54M | 1544.61M | -3399.55800M | 854.13M |
| Change in cash | -840.65000M | 523.41M | -1527.61800M | 1223.55M | 881.68M |
| Begin period cash flow | 3593.54M | 3070.13M | 4597.75M | 3374.19M | 2492.52M |
| End period cash flow | 2752.89M | 3593.54M | 3070.13M | 4597.75M | 3374.19M |
| Total cash from operating activities | 3911.33M | 2703.09M | 2666.59M | 2207.04M | 2344.02M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 66.36M | - |
| Depreciation | 963.90M | 709.84M | 514.79M | 408.01M | 497.51M |
| Other cashflows from investing activities | -2144.10600M | 127.88M | -5703.36000M | -10.19400M | -2.95400M |
| Dividends paid | -398.75200M | -391.68700M | -366.64800M | -343.57800M | 338.97M |
| Change to inventory | -2183.36800M | -665.37000M | -1116.34400M | -1621.14300M | -167.99000M |
| Change to account receivables | -2711.78600M | -1659.52500M | -930.07800M | -1628.99100M | -1241.89000M |
| Sale purchase of stock | -1180.72800M | -483.70400M | -82.15000M | -420.44900M | -674.03100M |
| Other cashflows from financing activities | -19.54000M | -48.19800M | -13.65500M | 126.06M | -16.66900M |
| Change to netincome | - | 434.10M | 244.55M | -1061.28500M | 621.95M |
| Capital expenditures | 458.36M | 496.32M | 438.22M | 369.68M | 310.22M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 874.54M | -139.66200M | 367.32M | 6664.40M | 363.38M |
| Stock based compensation | - | 93.40M | 99.59M | 74.41M | 58.87M |
| Other non cash items | 340.31M | 176.79M | -194.59000M | 4.75M | 541.59M |
| Free cash flow | 3452.97M | 2206.77M | 2228.37M | 1837.36M | 2033.80M |
Sector: Healthcare Industry: Medical Distribution
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| COR Cencora Inc. |
-4.43 1.93% | 224.77 | 23.39 | - | - | - | ||
| MCK McKesson Corporation |
-0.83 0.16% | 530.27 | 17.95 | 14.53 | 0.20 | 5.04 | 0.22 | 12.17 |
| CAH Cardinal Health Inc |
0.81 0.79% | 102.98 | 166.11 | 14.71 | 0.12 | 16.07 | 0.12 | 19.78 |
| HSIC Henry Schein Inc |
-0.18 0.26% | 68.60 | 21.82 | 14.33 | 0.76 | 2.63 | 0.92 | 12.98 |
| SHPMF Shanghai Pharmaceuticals Holding Co. Ltd |
- -% | 1.21 | 7.71 | 5.45 | 0.03 | 0.57 | 0.03 | 0.88 |
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
1 West First Avenue, Conshohocken, PA, United States, 19428-1800
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven H. Collis | Chairman, Pres & CEO | 1961 |
| Mr. James F. Cleary Jr. | Exec. VP & CFO | 1963 |
| Dr. Robert P. Mauch Ph.D., PharmD | Exec. VP & COO | 1967 |
| Ms. Gina K. Clark | Exec. VP and Chief Communications & Admin. Officer | 1957 |
| Mr. John G. Chou | Exec. VP and Special Advisor to the Chairman & CEO | 1956 |
| Mr. Lazarus Krikorian | Sr. VP, Chief Accounting Officer & Corp. Controller | 1965 |
| Bennett S. Murphy | Sr. VP of Investor Relations | NA |
| Ms. Kathy H. Gaddes | Exec. VP & Chief Compliance Officer | 1963 |
| Ms. Elizabeth S. Campbell | Exec. VP & Chief Legal Officer | 1975 |
| Ms. Silvana Battaglia | Exec. VP & Chief HR Officer | 1967 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...